Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... July 3, 2024 Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer July 23, 2020 Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... September 10, 2024 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Load more HOT NEWS COVID-19 Vaccine Myth Busters COVID-19 Vaccines: Considerations for Special Populations Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... A bug in the system – the difficulties of linking the...
